China Aoxing Pharmaceutical Company Announces Submission of NDA of Its Leading Narcotic Drug for the Treatment of Acute Moderate

  China Aoxing Pharmaceutical Company, Inc.
(OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in
research, development, manufacturing and marketing of narcotic and
pain-management products, today announced that it has submitted a new drug
application (NDA) to the China State Food and Drug Administration (SFDA)
for its Codeine Phosphate, a compound oral solution for the treatment of
acute moderate to severe cough.

Under the regulation of the China SFDA, this drug is designated as a Class III New Medicine, or the first drug to be launched in China while already selling in other regulated territories. As a result, the product is expected to receive at least three-year market exclusivity protection after marketing clearance by the China SFDA. In June 2009, China Aoxing announced that it had completed the clinical studies required for an NDA by the China SFDA. Assuming timely regulatory approval, the company expects to launch this product in China in 2010. China Aoxing believes that this product will give physicians a more effective option to the conventional drugs for the treatment of acute moderate to severe cough in China.

"This is a major achievement of our company. We believe that this drug will address a growing and presently unserved need in the marketplace, and we are very hopeful that the SFDA will find our submission acceptable for final production approval. We believe that we have adhered to the requirements we agreed upon with the SFDA at our pre-NDA meeting. We are also very pleased with the tremendous team effort, great planning and execution by our own staff," said Zhenjiang Yue, the Chairman and the CEO of China Aoxing.

The prevalence rate of cough condition is approximately at 15% in China. It is estimated that over 50 million Chinese patients are seeking cough treatment, mainly caused by respiratory disorders. The market size of pharmaceutical product to address cough condition is estimated approximately $2 billion per year with an annual growth rate of over 10% in China.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. It has a strategic alliance with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop and market various narcotic drugs in China. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-KSB for the year ended June 30, 2008, may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact: Wei Zhang China Aoxing Pharmaceutical Company, Inc. Email: [e-mail] Telephone: 646 - 367-1747 Website: www.chinapainmed.com